hotspot -WSS

hotspot

author：focus 2025-09-06 03:53:06 - browse：9

Diversity in clinical trials concept — Adobe

The persistent lack of diversity among participants in clinical trials is a critical issue that is harming both populations that have long been left out of pivotal medical studies and the entire biomedical research enterprise, according to the authors of a report released Tuesday by the National Academies of Sciences, Engineering and Medicine.

Describing the need to move away from trials that focus largely on white men as “urgent,” the report’s authors called for a paradigm shift that gives less power to institutions that fund and conduct clinical research and more to communities under study. The sternly worded report said funding to include and recruit more diverse participants should be a priority that is enforced and said such investments could eventually lead to massive cost savings as the nation’s health disparities are reduced.

“An equitable clinical research enterprise would include trials and studies that match the demographics of the disease burden under study,” the report said. “However, we remain far from achieving this goal.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： What don’t we know about an Alzheimer’s drug side effect?

WSS

HCA says smaller share of spending going to labor

Typhoon Doksuri makes landfall in China after bringing deadly landslides to Philippines

BIO selects John Crowley as new CEO

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

Trump PAC spent more than $40M on legal bills this year as his charges mount: Sources

Cigna, Humana reportedly in talks to merge

Wikipedia

hotspot

focus

Jerome Adams on the need for new antivirals for Covid

Despite FDA concern, risk that CAR

Medicare proposal to cover medical devices draws a mixed reaction

Doctors increasingly discourage vaping amid mounting health concerns

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What to do when lifesaving products contribute to climate change

Activists slam private health insurers over coverage restrictions

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

BioMarin wins approval for gene therapy to treat hemophilia A

Flagship Pioneering launches a new biotech in two countries

focus

Campaign finance charge dropped from case against Sam Bankman

U.K. Biobank has 500,000 peoples' genome sequences available

Fetal surgery at risk from Dobbs and new abortion restrictions

How to pay for weight loss drugs and save Medicare

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Europe is fastest

knowledge

focus

hotspot

entertainment